France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new ...

Q1 2025 Earnings Call Transcript April 25, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.46, expectations ...

Dupixent becomes the first-ever targeted therapy ... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.

Dermira’s chief development officer Luis Pena said recently he reckons lebrikizumab will be a strong rival to Dupixent thanks ... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks ...

“Dupixent is the first new targeted treatment for chronic spontaneous ... Regeneron Forward-Looking Statements and Use of Digital Media Regeneron uses its media and investor relations website and ...

Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...